Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company. Autoimmune biotech TRex Bio (TRXB) priced at the low end to raise $117...read more
TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, raised $117 million by offering 8.3 million shares at $14, the low end of the $14 to $16 range. Eli Lilly, an existing investor and partner, had indicated on $12 million...read more
TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to...read more
Updated Monday, 10/5. The fourth quarter is off to a quiet start with two biotech IPOs currently scheduled for the week ahead. Autoimmune biotech TRex Bio (TRXB) plans to raise $125 million at a $453 million market cap. The company's Deep Biology platform...read more
US IPO Weekly Recap: Biotech IPOs keep flowing as data center developer DayOne joins the pipeline
Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company. Autoimmune biotech TRex Bio (TRXB) priced at the low end to raise $117...read more
Autoimmune and inflammatory diseases biotech TRex Bio prices IPO at $14, the low end of the range
TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, raised $117 million by offering 8.3 million shares at $14, the low end of the $14 to $16 range. Eli Lilly, an existing investor and partner, had indicated on $12 million...read more
Autoimmune and inflammatory diseases biotech TRex Bio sets terms for $125 million IPO
TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to...read more
US IPO Week Ahead: Quiet start for the 4Q IPO market as Anthropic looms
Updated Monday, 10/5. The fourth quarter is off to a quiet start with two biotech IPOs currently scheduled for the week ahead. Autoimmune biotech TRex Bio (TRXB) plans to raise $125 million at a $453 million market cap. The company's Deep Biology platform...read more